secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001753926-26-000550
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani Medical reports FY2025 net loss $26.6M; advances semaglutide implant NPM-139 towards Phase 1
--------------------------------------------------------------------------------

- FY2025 net loss $26.6M vs $23.5M in FY2024; R&D expenses $18.1M up 15% YoY.
- Cash $16.2M as of Dec 31, 2025; raised $41.5M gross from financings; funds ops into mid-2027.
- Successful LIBERATE-1 first-in-human study; preclinical data shows >20% sham-adjusted weight loss for full year with single semaglutide implant.
- Phase 1 study of NPM-139 (semaglutide implant) for chronic weight management expected mid-2026 with results by end of 2026.
- Exploring spin-off or IPO of subsidiary Cortigent (neuromodulation assets).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392626000550/0001753926-26-000550-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392626000550/vani-20260326.htm
  HTML page:      https://secwatch.observer/filing/0001753926-26-000550

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer